[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fatty-liver-nonalcoholic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fatty-liver-nonalcoholic":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,78,102,140],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100431516","intermittent-fasting-for-nafld-in-adults-100431516",false,"NCT04899102","Intermittent Fasting for NAFLD in Adults","Pilot Study of Time-Restricted, Intermittent Fasting for Non-Alcoholic Fatty Liver Disease in Non-Obese Adults","Inclusion Criteria:\n\n1. Willing and able to provide informed consent\n2. Age 18 years or older at time of consent\n3. BMI 23-30kg\u002Fm\\^2 at screening\n4. Evidence of NAFLD confirmed by historical procedure obtained no more than 6 months prior to the screening visit, defined as:\n\n   * Grade \\>=1 steatosis on clinical liver biopsy; OR\n   * Fatty liver on validated imaging modality (non-contrast CT scan, MR Spectroscopy, MRI proton density fat fraction, ultrasound)\n5. Liver fat fraction ≥10% on H-MRS performed during the screening period\n6. Hepatitis C antibody and Hepatitis B surface antigen negative at screening\n\nExclusion Criteria:\n\n1. Heavy alcohol use for at least 3 consecutive months within the past 5 years prior to screening \\[heavy alcohol consumption is defined as: \\> 20g daily for women or \\> 30mg daily for men, assessed by the Lifetime Drinking History assessment at screening (23, 24)\\].\n2. Evidence of other known forms of chronic liver disease including:\n\n   • Alcoholic liver disease, hepatitis B, hepatitis C, PBC, PSC, autoimmune hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, drug-induced liver injury, known or suspected hepatocellular carcinoma (HCC).\n3. Current or prior history of Type II Diabetes requiring insulin or sulfonylureas due to risk of hypoglycemia with fasting.\n4. Use of any pharmacological treatments for NAFLD\u002FNASH within the 6 months prior to the screening visit, except vitamin E. Patients on a stable dose of vitamin E can be enrolled in the study.\n5. Unstable body weight \\[defined as: \\>10% reduction in body weight in the 6 months prior to the screening visit\\]\n6. Known cirrhosis, stage 4 fibrosis on prior liver biopsy, or clinical evidence of cirrhosis or portal hypertension on imaging or exam.\n7. Current or prior history of Child-Pugh score ≥7.\n8. History of liver transplant, or current placement on a liver transplant list.\n9. Known positivity for human immunodeficiency virus infection.\n10. Prior or planned bariatric surgery, patients on active pharmacological treatment for weight loss, or active involvement in a weight loss program.\n11. Routine MRI exclusion criteria, such as the presence of a pacemaker or cerebral aneurysm clip.\n12. Chronic Kidney Disease (CKD) with eGFR \\\u003C 60.\n13. For women of child-bearing potential (WOCBP): positive urine hCG, trying to achieve pregnancy, or breastfeeding \\[a negative urine pregnancy test is required at screening for women of child-bearing potential\\].\n14. Other medical conditions or severe chronic illnesses that, in the opinion of the Investigator, may present a contraindication to study participation.\n15. Any other condition that, in the opinion of the Investigator, may hinder study compliance or completion of the study schedule of assessments.","ALL","18 Years",{"count":19,"type":20},25,"ESTIMATED","INTERVENTIONAL",[23],"NA","NAFLD is a growing threat to public health. Currently, there is a significant need for highly effective treatments for NAFLD. Non-obese NAFLD (BMI\\\u003C30kg\u002Fm2) is an increasingly recognized condition, sometimes described as \"lean NAFLD\". Intermittent Fasting (IF) may be uniquely beneficial in non-obese NAFLD. The purpose of this study is to identify non-pharmacologic, lifestyle-based methods of NAFLD treatment within non-obese adults.",[26,27,28,29,30],"Fatty Liver","Intermittent Fasting","Fatty Liver, Nonalcoholic","Non-Alcoholic Fatty Liver Disease","Liver Fat",[26,27,32,33,34,35,30,29,28],"Non-obese","Diet","Nutrition","Time-restricted","RECRUITING","2025-12-10",{"date":39,"type":40},"2025-12-18","ACTUAL",{"date":42,"type":40},"2022-02-01",{"date":44,"type":20},"2026-07-31",{"name":46,"class":47},"Massachusetts General Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":48},"100574289","fatty-liver-and-pancreatic-steatosis-100574289","NCT06757348","Fatty Liver and Pancreatic Steatosis","Association Between Fatty Liver and Pancreatic Steatosis in Patients With Metabolic Syndrome","Inclusion Criteria:\n\n* Patients over 18 years old with a diagnosis of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).\n\nExclusion Criteria:\n\n* \\- Alcohol consumption \\>20 g\u002Fday in women, \\>30 g\u002Fday in men\n* Chronic hepatitis B or C infection\n* Autoimmune liver diseases: autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis\n* Hereditary hemochromatosis\n* Wilson's disease\n* Alpha-1 antitrypsin deficiency\n* Celiac disease\n* Uncontrolled thyroid disease\n* Active or chronic infectious disease\n* Active cancer or ongoing treatment\n* Chronic renal insufficiency\n* Pregnancy\u002Flactation\n* Insufficient data\n* Patients who do not complete follow-up","65 Years",{"count":58,"type":20},61,"OBSERVATIONAL","The goal of this observational study is to determine the prevalence of pancreatic steatosis in patients with fatty liver and determine the prevalence of exocrine pancreatic insufficiency (EPI) in these patients.\n\nParticipants with fatty liver and metabolic syndrome will undergo fecal elastase measurement and endoscopic ultrasound (EUS).",[62,28,63],"Exocrine Pancreatic Insufficiency","Pancreatic Steatosis",[65,66,67],"Fatty liver","Pancreatic steatosis","Metabolic syndrome","NOT_YET_RECRUITING","2025-08-05",{"date":71,"type":40},"2025-08-06",{"date":73,"type":20},"2025-09-01",{"date":75,"type":20},"2026-03-01",{"name":77,"class":47},"Maria Marta Piskorz",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":48},"100550306","prevalence-of-nafld-in-t1dm-patients-100550306","NCT06445361","Prevalence of NAFLD in T1DM Patients","The Prevalence of Non-Alcoholic Fatty Liver Disease in Type 1 Diabetes Mellitus Patients Followed at Ziekenhuis Oost-Limburg, Genk, Belgium","PAD1ZOL","Inclusion Criteria:\n\n* T1DM\n* ≥ 18 years of age\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Excessive alcohol use\n* Exclusion of other causes of liver disease and secondary causes of liver steatosis",{"count":87,"type":20},138,[23],"To determine the prevalence of NAFLD in T1DM patients.",[91,92,28],"NAFLD","Type 1 Diabetes","2025-07-22",{"date":95,"type":40},"2025-07-28",{"date":97,"type":40},"2023-07-01",{"date":99,"type":20},"2026-07-01",{"name":101,"class":47},"Ziekenhuis Oost-Limburg",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":113,"conditions":114,"keywords":121,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":48},"100598184","gepaktiv-vs-udca-and-ademetionine-in-mafld-with-hepatomegaly-100598184","NCT07068191","Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly","Randomized Comparative Clinical Study of the Dietary Supplement \"Gepaktiv\" (International Name: Phenomenon) in Comparison With Ursodeoxycholic Acid (UDCA) and Ademetionine in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) and Hepatomegaly","HEPACT","Inclusion Criteria:\n\n* Age 18 to 65 years\n* Confirmed diagnosis of metabolic-associated fatty liver disease (MAFLD)\n* Hepatomegaly confirmed by ultrasound (≥3 cm craniocaudal liver enlargement)\n* ALT level between 90-150 U\u002FL\n* Steatosis ≥260 dB\u002Fm by FibroScan (CAP)\n* Fibrosis ≥11 kPa by transient elastography (FibroScan)\n* Ability to comply with study procedures\n* Signed informed consent\n\nExclusion Criteria:\n\n* Liver cirrhosis or hepatocellular carcinoma\n* Pregnancy or lactation\n* Known allergy to any of the study medications or supplement components\n* Gallstones or biliary obstruction\n* Shrunken liver on imaging\n* Hepatic cysts (simple liver cysts\u002Fbiliary cysts)\n* Liver nodules (focal liver lesions)",{"count":111,"type":20},90,[23],"This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly).\n\nKey points:\n\n* Participants will receive either Gepaktiv, UDCA, or Ademetionine for 15 days\n* Doctors will monitor liver health through blood tests and ultrasound scans\n* The study will check if Gepaktiv helps improve liver function as effectively as standard treatments.\n\nMain measurements:\n\n* Changes in liver enzyme levels (ALT, AST)\n* Reduction in liver size\n* Improvement in fat accumulation (steatosis) measured by FibroScan This research may provide evidence for a new natural option to support liver health.Data analysis will be done by an independent biostatistics",[115,116,117,118,26,119,28,120],"Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)","Hepatomegaly","Nonalcoholic Fatty Liver (NAFL)","Nonalcoholic Fatty Liver Disease (NAFLD)","Fatty Liver, Alcoholic","Fatty Liver Disease",[116,122,123,124,125,126,127,128,129,130,26],"Gepaktiv","Metabolic dysfunction-associated fatty liver disease (MAFLD)","metabolic dysfunction-associated steatotic liver disease (MASLD)","Nonalcoholic fatty liver disease (NAFLD)","liver diseases","Nonalcoholic fatty liver (NAFL)","Liver","Liver steatosis","Dietary supplements","2025-07-19",{"date":133,"type":40},"2025-07-23",{"date":135,"type":40},"2025-06-19",{"date":137,"type":20},"2025-08",{"name":139,"class":47},"Phenomen Pharma",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":146,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":21,"phases":150,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":48},"100561895","lifestyle-changes-in-fatty-liver-additive-effect-of-honey-intake-100561895","NCT06596109","Lifestyle Changes in Fatty Liver; Additive Effect of Honey Intake","Inclusion Criteria:\n\n* fatty liver (non alcoholic form)\n* both sexes included\n* obese subjects (class I)\n\nExclusion Criteria:\n\n* cardiac insult\n* respiratory insult\n* renal insult\n* lower limb insult","30 Years","50 Years",{"count":149,"type":20},40,[23],"honey is a natural functional food used in control cardiovascular risk factors but its effect on fatty liver is not investigated",[28],"2024-09-11",{"date":155,"type":40},"2024-09-19",{"date":157,"type":40},"2024-09-10",{"date":159,"type":20},"2025-02-15",{"name":161,"class":47},"Cairo University"]